Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTP ICAP Regulatory News (TCAP)

Share Price Information for TP ICAP (TCAP)

Share Price is delayed by 15 minutes
Get Live Data
340.00    -1.40 (-0.41%)
Bid:
340.20
Ask:
340.40
Spread: 0.20 (0.059%)
Market Cap: £2.48b
TCAP Live PriceLast checked at - London Stock Exchange

Intraday TP ICAP Share Chart

Director Declaration

16 Nov 2018 15:42

RNS Number : 6692H
TP ICAP PLC
16 November 2018
 

TP ICAP PLC

 

16 November 2018

 

TP ICAP plc confirms regulatory approval of Nicolas Breteau

 

Following the appointment of Nicolas Breteau as Chief Executive on 10 July 2018, TP ICAP plc (the "Company") is pleased to confirm that on 14 November 2018 it received regulatory approval from the Financial Conduct Authority of Mr Breteau's appointment as Executive Director (CF1) at Tullet Prebon (Securities) Limited, ICAP Securities Limited and iSwap Euro Limited.

 

There are no other details that are required to be disclosed in respect of Mr Breteau's appointment under Paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.

 

ENDS

 

Media enquiries:

 

Jamie Dunkley

Jamie.Dunkley@tpicap.com

+44 (0) 20 7200 7524

 

About TPICAP

TP ICAP brings together buyers and sellers in global financial, energy and commodities markets. It is the world's largest wholesale market intermediary, with a portfolio of businesses that provide broking services, data & analytics and market intelligence, trusted by clients around the world. We operate from offices in 31 countries, supporting award-winning brokers with market-leading technology.

www.tpicap.com

 

About Nicolas Breteau

Nicolas Breteau has extensive experience across the global broking industry. He joined Tullett Prebon as Chief Commercial Officer in 2016, and then moved to run TP ICAP's largest business, Global Broking.

Nicolas started his career in 1993 on the Listed Derivatives Exchange MATIF (later part of Euronext). From 1993 to 1998, he held several senior positions at the derivatives broker FIMAT, including Deputy CEO of the

Paris Office. He then moved to London as Head of Risk for EMEA, and subsequently became Deputy CEO then CEO of the FIMAT London Branch.

In 2005, Nicolas was promoted to CEO of EMEA, a position he consolidated after Newedge was formed through the merger of FIMAT with Calyon Financial in 2008. He was appointed Global Head of Sales and Front-Office in 2009 and became Chief Executive of Newedge Group in 2010. He moved from Newedge in 2014 following the sale of the company to Société Générale, and became Senior Managing Partner of a consulting firm, 99 Advisory.

Nicolas graduated from Ecole Superieure de Commerce de Bordeaux. He has been a director of several Boards including the Futures and Options Association (UK), Futures Industry Association (USA), Altura (Spain), Citic/Newedge (China) and has been the chairman of i-swap since February 2018.

He is a trustee at PSE For a Child's Smile UK, which helps deprived children in Cambodia.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNUNSVRWRAAAAA
Date   Source Headline
26th Mar 20181:26 pmRNSAllotment of consideration shares
26th Mar 201811:01 amRNSDirector/PDMR Shareholding
14th Mar 20185:19 pmRNSDirector/PDMR Shareholding
13th Mar 20187:00 amRNSFinal Results
8th Jan 20187:00 amRNSAcquisition
5th Jan 20181:24 pmRNSTotal Voting Rights
5th Jan 20187:00 amRNSNotice of Results
15th Dec 20177:00 amRNSDirector/PDMR Shareholding
8th Dec 201712:52 pmRNSHolding(s) in Company
8th Dec 20177:00 amRNSDirectorate Change
30th Nov 20177:00 amRNSAcquisition of Coex Partners Limited
30th Nov 20177:00 amRNSCapital Markets Update
29th Nov 20173:45 pmRNSDirector/PDMR Shareholding
23rd Nov 20174:26 pmRNSHolding(s) in Company
22nd Nov 201711:54 amRNSHolding(s) in Company
3rd Nov 20177:00 amRNS3rd Quarter Trading Update
17th Oct 20177:00 amRNSDirectorate Change
5th Oct 20179:58 amRNSHolding(s) in Company
29th Sep 20178:21 amRNSHolding(s) in Company
22nd Sep 20173:58 pmRNSHolding(s) in Company
22nd Sep 201712:28 pmRNSHolding(s) in Company
30th Aug 20173:33 pmRNSHolding(s) in Company
8th Aug 20177:00 amRNSFinancial and Interim Management Report
17th Jul 201710:33 amRNSHolding(s) in Company
14th Jul 201712:38 pmRNSHolding(s) in Company
22nd Jun 20179:53 amRNSHolding(s) in Company
16th Jun 201711:37 amRNSHolding(s) in Company
22nd May 20173:02 pmRNSDirector/PDMR Shareholding
15th May 20172:52 pmRNSDirector/PDMR Shareholding
11th May 20174:45 pmRNSResult of Annual General Meeting
11th May 20177:02 amRNSBalance Sheet Strengthens with £270m Bulk Annuity
11th May 20177:00 amRNSAGM Statement and Trading Update
6th Apr 201711:00 amRNSAnnual Financial Report
5th Apr 201711:57 amRNSDirector/PDMR Shareholding
27th Mar 20174:41 pmRNSDirector/PDMR Shareholding
14th Mar 20177:00 amRNSFinal Results
28th Feb 201712:27 pmRNSNotice of Results
21st Feb 20179:29 amRNSHolding(s) in Company
24th Jan 20176:04 pmRNSTP ICAP GBP 7yr - Post-Stabilisation Notice
24th Jan 20174:42 pmRNSPublication of Final Terms
19th Jan 20175:29 pmRNSIssue of £500m Fixed Rate Senior Unsecured Notes
19th Jan 20178:39 amRNSTP ICAP GBP 7yr - Pre-Stabilisation Notice
18th Jan 201711:03 amRNSPublication of a Prospectus
16th Jan 20176:06 pmRNSHolding(s) in Company
12th Jan 20174:47 pmRNSHolding(s) in Company
12th Jan 20174:42 pmRNSHolding(s) in Company
12th Jan 20174:28 pmRNSHolding(s) in Company
10th Jan 201710:12 amRNSHolding(s) in Company
6th Jan 201710:54 amRNSPublication of a Prospectus
6th Jan 20177:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.